This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
3. GH Friedland , Intravenous drug abusers and the acquired immunodeficiency syndrome (AIDS) Demographic, drug use, and needle-sharing patterns. Archives of Internal Medicine 1985; 145: 1413–1417.
6. C Matheï , F Buntinx , P van Damme . Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. Journal of Viral Hepatitis 2002; 9: 157–173.
8. L Wiessing , Associations between availability and coverage of HIV prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. American Journal of Public Health 2009; 99: 1049–1052.
9. BM Mathers , for the 2009 Reference Group to the UN on HIV and Injecting Drug Use. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375: 1014–1028.
13. D Hedrich , A Pirona , L. Wiessing From margin to mainstream: the evolution of harm reduction responses to problem drug use in Europe. Drugs Education Prevention and Policy 2008; 15: 503–517.
15. T Zabransky , Hepatitis C virus infection among injecting drug users in the Czech Republic – prevalence and associated factors. European Addiction Research 2006; 12: 151–160.
17. L Camoni , , SerT Study Group.Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy. Annali dell'Istituto Superiore di Sanità 2010; 46: 59–65.
18. L Camoni , , SerT Study Group.Prevalence and correlates of infection with human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among drug users in Italy: a cross-sectional study. Scandinavian Journal of Infectious Diseases 2009; 41: 521–523.
A Taylor ,
Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990–1996: are current harm reduction strategies working?
Journal of Infection
2000; 40: 176–183.
SJ Hutchinson ,
Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990–94: implications for control and prevention of blood-borne viruses. Addiction
2000; 95: 931–40.
23. SF Greenfield , Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug and Alcohol Dependence 2007; 86: 1–21.
24. MT Schechter , Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak. AIDS 1999; 13: F45–51.
25. L Platt , Measuring risk of HIV and HCV among injecting drug users in the Russian Federation. European Journal of Public Health 2009; 19: 428–433.
26. MJ Alter . Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology 2007; 13: 2436–2441.
28. CE Lindenburg , Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS 2006; 20: 1771–1775.
32. AS Abdul-Quader , Effectiveness of respondent-driven sampling for recruiting drug users in New York City: findings from a pilot study. Journal of Urban Health 2006; 83: 459–476.
33. D Heckathorn, Douglas . Respondent-driven sampling: a new approach to the study of hidden populations. Social Problems 1997; 44: 174–199.
34. M Malekinejad , Accessing a diverse sample of injection drug users in San Francisco through respondent-driven sampling. Drug and Alcohol Dependence 2011; 118: 83–91.
35. A Uusküla , Evaluating recruitment among female sex workers and injecting drug users at risk for HIV using respondent-driven sampling in Estonia. Journal of Urban Health 2010; 87: 304–317.
36. AE Rudolph , Subpopulations of illicit drug users reached by targeted street outreach and respondent-driven sampling strategies: implications for research and public health practice. Annals of Epidemiology 2011; 21: 280–289.